ICER

ICER-VA alliance for formulary management sparks debateThe National Pharmaceutical Council takes issue with ICER’s collaboration with the VA’s PBM. Find out what both camps are saying.
Survey: How payers use nonpayer generated data to make formulary decisionsExternal, non-payer generated data can inform formulary decision-making—if payers know their strengths and weaknesses.
Abuse-Deterrent Opioids Aren’t Effective
Abuse-Deterrent Opioids Aren’t EffectiveNew research suggests that the latest trend in opioids may not be so helpful.
ICER, VA join to work on drug value, price negotiationsAnalysts discuss how pharmacoeconomics will make a difference in treatment decisions.
The Future of Oncology Treatment Is Value AssessmentHow value assessment tools enhance decision-making in oncology.
Real-world results determine value-based price for specialty drugsIn an era when adherence to specialty pharmaceuticals is disturbingly low, value-based pricing needs real-world results, not single-arm accelerated trials.